These include peptide-based approaches such as CT20p, a peptide derived from Bax that has been demonstrated to specifically bind to the CCTβ subunit and preferentially trigger apoptosis in cancer cells, providing proof-of-concept for targeted CCT intervention [23,105]. Here, CCT2 is linked to cancer.